Marmolejo DH - Search Results

1

Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.

Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3. Marmolejo DH, et al. Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1. Eur J Med Genet. 2021. PMID: 34606975 Review.

2

Up-to-date role of aflibercept in the treatment of colorectal cancer.

Saoudi Gonzalez N, Salvà F, Ros J, Baraibar I, Marmolejo D, Valdivia A, Cuadra-Urteaga JL, Mulet N, Tabernero J, Élez E. Saoudi Gonzalez N, et al. Expert Opin Biol Ther. 2021 Oct;21(10):1315-1324. doi: 10.1080/14712598.2021.1935231. Epub 2021 Jun 13. Expert Opin Biol Ther. 2021. PMID: 34085884 Review.

3

Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.

Mirallas O, Marmolejo D, Valdivia A, Vieito M. Mirallas O, et al. BMJ Case Rep. 2020 Apr 6;13(4):e233708. doi: 10.1136/bcr-2019-233708. BMJ Case Rep. 2020. PMID: 32265210 Free PMC article.

4

Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease.

Suarez C, Marmolejo D, Valdivia A, Morales-Barrera R, Gonzalez M, Mateo J, Semidey ME, Lorente D, Trilla E, Carles J. Suarez C, et al. Front Oncol. 2022 Oct 4;12:970199. doi: 10.3389/fonc.2022.970199. eCollection 2022. Front Oncol. 2022. PMID: 36267983 Free PMC article. Review.

5

Interrelations between Patients' Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients.

Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N, Amat R, Felip E. Callejo A, et al. Cancers (Basel). 2021 Jun 29;13(13):3249. doi: 10.3390/cancers13133249. Cancers (Basel). 2021. PMID: 34209601 Free PMC article.

6

Response to "Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias".

Villacampa G, Hernando-Calvo A, Berché R, Saavedra O, Marmolejo D, Mirallas O, Braña I, Muñoz-Couselo E, Garralda E, Dienstmann R. Villacampa G, et al. Cancer Treat Rev. 2022 Dec;111:102465. doi: 10.1016/j.ctrv.2022.102465. Epub 2022 Sep 23. Cancer Treat Rev. 2022. PMID: 36209603 No abstract available.

7

Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort.

Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A, Carbonell C, Frigola J, Amat R, Pedrola A, Dienstmann R, Felip E. Cedres S, et al. Sci Rep. 2021 Nov 1;11(1):21357. doi: 10.1038/s41598-021-00831-4. Sci Rep. 2021. PMID: 34725384 Free PMC article.

8

Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors.

Riveiro-Barciela M, González-Sans D, Marmolejo D, Salcedo MT, Muñoz-Couselo E. Riveiro-Barciela M, et al. J Gastrointestin Liver Dis. 2021 Mar 13;30(1):171-172. doi: 10.15403/jgld-3207. J Gastrointestin Liver Dis. 2021. PMID: 33723557 Free article. No abstract available.

9

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. Scirica BM, et al. N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2. N Engl J Med. 2013. PMID: 23992601 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page